Insider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells 4,148 Shares of Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,148 shares of the firm’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $36.16, for a total transaction of $149,991.68. Following the completion of the sale, the chief financial officer now owns 102,464 shares in the company, valued at approximately $3,705,098.24. The trade was a 3.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

BridgeBio Pharma Trading Up 2.3 %

BBIO stock traded up $0.80 during trading on Wednesday, hitting $36.29. The company had a trading volume of 4,162,895 shares, compared to its average volume of 2,811,407. The company has a fifty day moving average price of $31.53 and a two-hundred day moving average price of $27.79. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $37.81. The company has a market cap of $6.86 billion, a P/E ratio of -15.06 and a beta of 1.07.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Scotiabank increased their price target on shares of BridgeBio Pharma from $48.00 to $49.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 12th. Bank of America lifted their target price on BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Evercore ISI upped their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $49.00 price objective on shares of BridgeBio Pharma in a report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, BridgeBio Pharma has a consensus rating of “Moderate Buy” and an average price target of $49.08.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC increased its position in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after purchasing an additional 472 shares in the last quarter. Itau Unibanco Holding S.A. bought a new stake in BridgeBio Pharma during the fourth quarter worth about $41,000. Sterling Capital Management LLC increased its holdings in shares of BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after buying an additional 1,514 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of BridgeBio Pharma in the third quarter valued at approximately $57,000. Finally, CWM LLC boosted its holdings in shares of BridgeBio Pharma by 132.9% in the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after acquiring an additional 1,964 shares in the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.